Introduction: Clinical outcomes of patients with stable coronary artery disease (SCAD) may differ between those primarily managed by cardiologists versus non-cardiologists. Objectives: Our main objective was to analyze the clinical outcomes of outpatients with SCAD in relation to the specialty of the managing physicians. Patients and methods: We studied 32,468 outpatients with SCAD included in the CLARIFY registry, with up to 4 years follow-up data. Cardiologists provided medical care in 84.1%, and non-cardiologists in 15.9% of patients. Primary outcome was the composite of cardiovascular death, non-fatal myocardial infarction (MI), or stroke. Results: Important differences in demographics, clinical characteristics, and management wer...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
AIMS: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
textabstractOBJECTIVES: Examination of the difference in management strategies with respect to coron...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
AIMS: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
INTRODUCTION Clinical outcomes of patients with stable coronary artery disease (CAD) may differ betw...
textabstractOBJECTIVES: Examination of the difference in management strategies with respect to coron...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
Aims: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...
AIMS: We evaluated the 1-year clinical events, pharmacological management, and quality of life in a ...